CRT slides: Data and safety monitoring boards—friend or foe to CV trials?

Justine Varieur Cadet | | Cardiovascular Business | Patient Care

WASHINGTON, D.C.—Independent data and safety monitoring boards are a necessary component of any cardiovascular trial involving human participants, but they have received a great deal of scrutiny due to some controversies about decision-making. Ajay J. Kirtane, MD, explained the legal role and responsibilities of these powerful oversight arms of trials.  

About the presenter:

Kirtane is the chief academic officer and director of the interventional cardiology fellowship program at Columbia University Medical Center/NewYork-Presbyterian Hospital in New York City.

Justine Varieur Cadet

Related Content

ACC offers practical approaches for arrhythmia monitoring after stroke
FDA and Boston Scientific issue urgent alert about pacemaker failures following 2 deaths
Concomitant ablation surgery during heart operations boosts long-term survival
Cardiologist explores why colchicine failed to help heart attack patients
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Most heart failure patients miss out on guideline-recommended palliative care

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.